Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC reduced its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 71.1% during the 2nd quarter, Holdings Channel reports. The fund owned 49,900 shares of the company’s stock after selling 123,000 shares during the quarter. Renaissance Technologies LLC’s holdings in Sana Biotechnology were worth $272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Hartline Investment Corp acquired a new position in shares of Sana Biotechnology during the first quarter valued at $136,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Sana Biotechnology by 20.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock valued at $163,000 after buying an additional 5,090 shares in the last quarter. Arizona State Retirement System increased its stake in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after buying an additional 9,940 shares during the period. ProShare Advisors LLC increased its stake in Sana Biotechnology by 14.8% during the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock valued at $327,000 after buying an additional 4,210 shares during the period. Finally, Clarius Group LLC raised its position in shares of Sana Biotechnology by 34.9% during the 2nd quarter. Clarius Group LLC now owns 63,184 shares of the company’s stock worth $345,000 after buying an additional 16,359 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.99 on Friday. Sana Biotechnology, Inc. has a 12 month low of $2.74 and a 12 month high of $12.00. The company has a market capitalization of $883.80 million, a P/E ratio of -2.61 and a beta of 1.42. The company’s 50 day simple moving average is $4.81 and its 200 day simple moving average is $6.51.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, analysts anticipate that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

SANA has been the subject of several recent analyst reports. Citigroup increased their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 9th. Rodman & Renshaw began coverage on Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright dropped their price objective on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, August 9th.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the transaction, the director now owns 2,848,121 shares in the company, valued at $11,620,333.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 31.10% of the stock is owned by insiders.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.